| SC 13G | 2021-02-12 | CREDIT SUISSE AG/ | UroGen Pharma Ltd. | 1,121,071 | 507.0% | EDGAR |
| SC 13G/A | 2021-02-11 | MENORA MIVTACHIM HOLDINGS LTD. | UroGen Pharma Ltd. | 2,954,699 | 13.4% | EDGAR |
| SC 13G/A | 2021-02-03 | WELLINGTON MANAGEMENT GROUP LLP | UroGen Pharma Ltd. | 1,840,637 | 8.3% | EDGAR |
| SC 13G/A | 2021-02-01 | BlackRock Inc. | UroGen Pharma Ltd. | 1,529,491 | 6.9% | EDGAR |
| SC 13G/A | 2020-02-14 | Consonance Capital Management LP | UroGen Pharma Ltd. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-14 | Wildcat Capital Management, LLC | UroGen Pharma Ltd. | 533,139 | 2.5% | EDGAR |
| SC 13D/A | 2020-02-12 | Arkin Moshe | UroGen Pharma Ltd. | - | 6.5% | EDGAR |
| SC 13G/A | 2020-02-12 | MENORA MIVTACHIM HOLDINGS LTD. | UroGen Pharma Ltd. | 2,954,699 | 14.1% | EDGAR |
| SC 13G | 2020-02-07 | BlackRock Inc. | UroGen Pharma Ltd. | 1,372,863 | 6.5% | EDGAR |
| SC 13G/A | 2020-01-27 | WELLINGTON MANAGEMENT GROUP LLP | UroGen Pharma Ltd. | 1,290,597 | 6.2% | EDGAR |
| SC 13G | 2019-10-04 | Wildcat Capital Management, LLC | UroGen Pharma Ltd. | 533,139 | 2.6% | EDGAR |
| SC 13D/A | 2019-06-03 | Arkin Moshe | UroGen Pharma Ltd. | - | 6.6% | EDGAR |
| SC 13G/A | 2019-02-14 | Consonance Capital Management LP | UroGen Pharma Ltd. | 1,450,885 | 9.0% | EDGAR |
| SC 13G/A | 2019-02-14 | MENORA MIVTACHIM HOLDINGS LTD. | UroGen Pharma Ltd. | 2,499,870 | 12.6% | EDGAR |
| SC 13G/A | 2019-02-13 | FMR LLC | UroGen Pharma Ltd. | 556,003 | 3.5% | EDGAR |
| SC 13G | 2019-02-12 | WELLINGTON MANAGEMENT GROUP LLP | UroGen Pharma Ltd. | 973,154 | 6.0% | EDGAR |
| SC 13G/A | 2019-01-11 | ProQuest Investments IV, L.P. | UroGen Pharma Ltd. | 789,297 | 4.9% | EDGAR |
| SC 13D | 2018-05-24 | Arkin Moshe | UroGen Pharma Ltd. | - | 9.4% | EDGAR |
| SC 13D | 2018-02-15 | Pontifax Management III G.P. (2011) Ltd. | UroGen Pharma Ltd. | 1 | 10.6% | EDGAR |
| SC 13G/A | 2018-02-14 | ProQuest Investments IV, L.P. | UroGen Pharma Ltd. | 1,096,024 | 7.1% | EDGAR |